Related Experiment Video
Updated: Jun 28, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
CXCR4 mediates the proliferation of glioblastoma progenitor cells
Moneeb Ehtesham1, Khubaib Y Mapara, Charles B Stevenson
1Department of Neurological Surgery, Vanderbilt University Medical Center, 21st Avenue & Garland Street, Nashville, TN 37232, USA. moneeb.ehtesham@vanderbilt.edu
Abstract:
Increasing evidence points to a fundamental role for cancer stem cells (CSC) in the initiation and propagation of many tumors. As such, in the context of glioblastoma multiforme (GBM), the development of treatment strategies specifically targeted towards CSC-like populations may hold significant therapeutic promise. To this end, we now report that the cell surface chemokine receptor, CXCR4, a known mediator of cancer cell proliferation and invasion, is overexpressed in primary glioblastoma progenitor cells versus corresponding differentiated tumor cells. Furthermore, administration of CXCL12, the only known ligand for CXCR4, stimulates a specific and significant proliferative response in progenitors but not differentiated tumor cells. Taken together, these results implicate an important role for the CXCR4 signaling mechanism in glioma CSC biology and point to the therapeutic potential of targeting this pathway in patients with GBM.
Insights
Cancer stem cells (CSCs) drive tumor growth. Targeting the CXCR4 pathway in glioblastoma (GBM) CSCs shows therapeutic promise by inhibiting proliferation.
Area of Science:
- Oncology
- Cancer Biology
- Neuro-oncology
Background:
- Cancer stem cells (CSCs) are crucial for tumor initiation and progression in various cancers.
- Glioblastoma multiforme (GBM) is an aggressive brain tumor where CSCs play a significant role.
- Targeting CSCs presents a promising therapeutic strategy for GBM.
Purpose of the Study:
- To investigate the role of the chemokine receptor CXCR4 in glioblastoma CSC biology.
- To determine if targeting the CXCR4 pathway could be a viable therapeutic approach for GBM.
Main Methods:
- Quantitative analysis of CXCR4 expression in primary glioblastoma progenitor cells versus differentiated tumor cells.
- Assessing the proliferative response of glioblastoma progenitor and differentiated cells to CXCL12 stimulation.
Main Results:
- CXCR4 is overexpressed in glioblastoma progenitor cells compared to differentiated tumor cells.
- CXCL12 significantly stimulates proliferation in glioblastoma progenitor cells but not in differentiated tumor cells.
- These findings highlight the CXCR4 signaling pathway's involvement in glioma CSC biology.
Conclusions:
- The CXCR4 signaling pathway is implicated in the biology of glioma CSCs.
- Targeting the CXCR4 pathway offers potential therapeutic benefits for patients with GBM.
